Cyclerion Therapeutics, INC

Cyclerion Therapeutics and privately-held Korsana Biosciences announced a definitive merger agreement and a concurrent $380 million private financing to advance Korsana's neurodegenerative disease pipeline, including a lead Alzheimer's program.

Cyclerion Therapeutics announced positive FDA feedback for its lead product candidate, CYC-126, and formed a Clinical Advisory Board, staying on track for a Phase 2 study in Treatment Resistant Depression.

Cyclerion Therapeutics announced a strategic collaboration with Medsteer to enhance its anesthetic delivery platform for CYC-126 in treatment-resistant depression, targeting a Phase 2 study in H2 2026.

Cyclerion Therapeutics is set to receive a $1.0 million milestone payment from Akebia Therapeutics following the initiation of Phase 2 clinical trials for Praliciguat in focal segmental glomerulosclerosis.

Cyclerion Therapeutics has announced a transformational relaunch, securing an exclusive license from MIT to develop therapies for neuropsychiatric disorders, starting with treatment-resistant depression.

Cyclerion Therapeutics, Inc. announced the results of its Annual Meeting of Shareholders held on June 16, 2025, where all director nominees were re-elected, Ernst & Young LLP was ratified as the independent auditor, and executive compensation was approved.

Cyclerion Therapeutics' Q2 2026 10-Q filing reveals substantial doubt about its ability to continue as a going concern, alongside details of a proposed merger with Korsana Biosciences.

Cyclerion Therapeutics reports Q1 2026 results, highlighting a significant net loss and ongoing preparations for a merger with Korsana Biosciences, while facing substantial going concern doubts.

Cyclerion Therapeutics reports reduced net losses and increased revenue, secures a new license for treatment-resistant depression, but faces substantial doubt about its ability to continue as a going concern.

Cyclerion Therapeutics reports a reduced net loss and improved operating cash flow for Q2 2025, driven by an insurance recovery and new financing, but faces substantial doubt about its ability to continue as a going concern.

Cyclerion Therapeutics reports a net loss of $1.429 million for the first quarter of 2025 and discusses its strategic focus on neuropsychiatric diseases, particularly treatment-resistant depression (TRD).

Cyclerion Therapeutics' Q3 2024 results show a net loss, but include revenue from a new option agreement and reduced operating expenses.

Cyclerion Therapeutics, Inc. files an amendment to its 2025 10-K to include Part III information and new executive certifications.

Cyclerion Therapeutics, Inc. filed an amendment to its 2024 Annual Report, adding a critical audit matter regarding its investment in Tisento Therapeutics Holdings Inc. while reaffirming its going concern warning.

Cyclerion Therapeutics is pivoting towards neuropsychiatric therapeutics, particularly treatment-resistant depression, while facing substantial doubt about its ability to continue as a going concern.

Cyclerion Therapeutics' 2023 10-K filing details a strategic shift away from CNS-focused sGC stimulators, the sale of key assets, and a focus on building a new portfolio.

Cyclerion Therapeutics announces progress on its merger with Korsana Biosciences, highlighting potential advancements in neurodegenerative disease therapies.

Cyclerion Therapeutics announces progress on its merger with Korsana Biosciences, detailing forward-looking statements and regulatory filings.

Cyclerion Therapeutics and Korsana Biosciences have entered into a merger agreement, aiming to combine their operations and advance drug development pipelines.

Korsana Biosciences announces key executive and board appointments to advance its lead Alzheimer's candidate, KRSA-028, and prepare for its merger with Cyclerion Therapeutics.

Peter M Hecht, a Director and 10% owner of Cyclerion Therapeutics, Inc., reported multiple transactions in common stock on July 16, 2026.

Korsana Biosciences announces a reverse merger with Cyclerion Therapeutics, aiming to advance its novel Alzheimer's therapy, KRSA-028, with a $380M financing.

Cyclerion Therapeutics has filed a definitive proxy statement with the SEC.

Cyclerion Therapeutics will hold its annual shareholder meeting virtually on June 16, 2025, to vote on director elections, auditor ratification, executive compensation, and other proposals.

Cyclerion Therapeutics has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Cyclerion Therapeutics announces its Annual Meeting of Shareholders to be held virtually on June 14, 2024, to vote on director elections, auditor ratification, and an adjournment proposal.

Peter M. Hecht amends Schedule 13D, reporting a beneficial ownership of 910,240 shares of Cyclerion Therapeutics' common stock, representing 19.4% of the class.

Peter M. Hecht, a significant shareholder, increased his beneficial ownership in Cyclerion Therapeutics, Inc. to 27.9% through a recent private placement of common stock.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 7.0% of Cyclerion Therapeutics, Inc. common stock as of June 30, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 317,511 shares, representing 7.33% of Cyclerion Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 15.0% of Cyclerion Therapeutics Inc.'s common stock as of April 30, 2026.

J. Wood Capital Advisors LLC and Jason Wood have disclosed a 5.4% beneficial ownership stake in Cyclerion Therapeutics, Inc., holding 181,818 shares of common stock.

Tyndall Capital Partners, L.P. reports a 4.8% passive ownership stake in Cyclerion Therapeutics, Inc. as of June 30, 2025.

Tyndall Capital Partners, L.P. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Cyclerion Therapeutics, Inc. as of March 31, 2025.